An entirely subcutaneous implantable cardioverter-defibrillator

Gust H. Bardy, Warren M. Smith, Margaret A. Hood, Ian G. Crozier, Iain C. Melton, Luc Jordaens, Dominic Theuns, Robert E. Park, David J. Wright, Derek T. Connelly, Simon P. Fynn, Francis D. Murgatroyd, Johannes Sperzel, Jörg Neuzner, Stefan G. Spitzer, Andrey V. Ardashev, Amo Oduro, Lucas Boersma, Alexander H. Maass, Isabelle C. Van GelderArthur A. Wilde, Pascal F. Van Dessel, Reinoud E. Knops, Craig S. Barr, Pierpaolo Lupo, Riccardo Cappato, Andrew A. Grace

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND: Implantable cardioverter-defibrillators (ICDs) prevent sudden death from cardiac causes in selected patients but require the use of transvenous lead systems. To eliminate the need for venous access, we designed and tested an entirely subcutaneous ICD system. METHODS: First, we conducted two shortterm clinical trials to identify a suitable device configuration and assess energy requirements. We evaluated four subcutaneous ICD configurations in 78 patients who were candidates for ICD implantation and subsequently tested the best configuration in 49 additional patients to determine the subcutaneous defibrillation thresh old in comparison with that of the standard transvenous ICD. Then we evaluated the longterm use of subcutaneous ICDs in a pilot study, involving 6 patients, which was followed by a trial involving 55 patients. RESULTS: The best device configuration consisted of a parasternal electrode and a left lateral thoracic pulse generator. This configuration was as effective as a transvenous ICD for terminating induced ventricular fibrillation, albeit with a significantly higher mean (±SD) energy requirement (36.6±19.8 J vs. 11.1±8.5 J). Among patients who received a permanent subcutaneous ICD, ventricular fibrillation was successfully detected in 100% of 137 induced episodes. Induced ventricular fibrillation was converted twice in 58 of 59 patients (98%) with the delivery of 65J shocks in two consecutive tests. Clinically significant adverse events included two pocket infections and four lead revisions. After a mean of 10±1 months, the device had successfully detected and treated all 12 episodes of spontaneous, sustained ventricular tachyarrhythmia. CONCLUSIONS: In small, nonrandomized studies, an entirely subcutaneous ICD consistently detected and converted ventricular fibrillation induced during electrophysiological testing. The device also successfully detected and treated all 12 episodes of spontaneous, sustained ventricular tachyarrhythmia. (ClinicalTrials.gov numbers, NCT00399217 and NCT00853645.).

Original languageEnglish
Pages (from-to)36-44
Number of pages9
JournalNew England Journal of Medicine
Volume363
Issue number1
DOIs
Publication statusPublished - Jul 1 2010

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'An entirely subcutaneous implantable cardioverter-defibrillator'. Together they form a unique fingerprint.

Cite this